<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: The aim of this study was a prospective validation of the World Health Organization (WHO) proposals for the classification of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with respect to their prognostic relevance </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: We classified 1095 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosed at our institution between November 1999 and December 2004 according to French-American-British (FAB) and WHO criteria by central morphologic review </plain></SENT>
<SENT sid="2" pm="."><plain>The study was not population-based, but included <z:hpo ids='HP_0000001'>all</z:hpo> newly diagnosed patients from different regions in Germany </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were followed for survival and disease evolution to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) through December 31th, 2005 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: According to the WHO classification, there were 89 cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 293 of refractory cytopenias with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), 31 RA with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 139 RCMD with ringed sideroblasts (<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>), 142 RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) I and 149 RAEB II and 52 patients with <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The median survival of patients with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> was not reached, the median survival of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> was 31 months, that of patients with <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> was 28 months, that of 5q- patients was 40 months, of <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> 27 months and of <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> 12 months </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolution 2 years after diagnosis was 0% in RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 8% in 5q-, 9% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, 12% in <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>, 13% in <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> and 40% in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The number of high-risk karyotypes was lower in patients with RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> than in those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>/<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> and <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e>/<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Karyotype findings were major prognostic variables </plain></SENT>
<SENT sid="9" pm="."><plain>INTERPRETATION AND CONCLUSIONS: The WHO classification is feasible and provides valuable prognostic information, even in a short-term prospective study </plain></SENT>
<SENT sid="10" pm="."><plain>Together with cytogenetic data and other prognostic parameters, the WHO classification is very useful for clinical decision making </plain></SENT>
</text></document>